231 related articles for article (PubMed ID: 31752944)
1. Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth.
Cisse O; Quraishi M; Gulluni F; Guffanti F; Mavrommati I; Suthanthirakumaran M; Oh LCR; Schlatter JN; Sarvananthan A; Broggini M; Hirsch E; Falasca M; Maffucci T
J Exp Clin Cancer Res; 2019 Nov; 38(1):472. PubMed ID: 31752944
[TBL] [Abstract][Full Text] [Related]
2. Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.
Chikh A; Ferro R; Abbott JJ; Piñeiro R; Buus R; Iezzi M; Ricci F; Bergamaschi D; Ostano P; Chiorino G; Lattanzio R; Broggini M; Piantelli M; Maffucci T; Falasca M
Oncotarget; 2016 Apr; 7(14):18325-45. PubMed ID: 26934321
[TBL] [Abstract][Full Text] [Related]
3. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
[TBL] [Abstract][Full Text] [Related]
5. Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion.
Mavrommati I; Cisse O; Falasca M; Maffucci T
Sci Rep; 2016 Mar; 6():23277. PubMed ID: 26983806
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the Class II PI3K-C2β Potentiates Insulin Signaling and Sensitivity.
Alliouachene S; Bilanges B; Chicanne G; Anderson KE; Pearce W; Ali K; Valet C; Posor Y; Low PC; Chaussade C; Scudamore CL; Salamon RS; Backer JM; Stephens L; Hawkins PT; Payrastre B; Vanhaesebroeck B
Cell Rep; 2015 Dec; 13(9):1881-94. PubMed ID: 26655903
[TBL] [Abstract][Full Text] [Related]
7. The class II phosphoinositide 3-kinases PI3K-C2α and PI3K-C2β differentially regulate clathrin-dependent pinocytosis in human vascular endothelial cells.
Aung KT; Yoshioka K; Aki S; Ishimaru K; Takuwa N; Takuwa Y
J Physiol Sci; 2019 Mar; 69(2):263-280. PubMed ID: 30374841
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
9. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
Gruber M; Handle F; Culig Z
Prostate; 2020 Feb; 80(3):267-273. PubMed ID: 31834633
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
11. miR-362-5p inhibits proliferation and migration of neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2β.
Wu K; Yang L; Chen J; Zhao H; Wang J; Xu S; Huang Z
FEBS Lett; 2015 Jul; 589(15):1911-9. PubMed ID: 26073258
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3-kinase-C2β inhibits cisplatin-mediated apoptosis via the Akt pathway in oesophageal squamous cell carcinoma.
Liu Z; Sun C; Zhang Y; Ji Z; Yang G
J Int Med Res; 2011; 39(4):1319-32. PubMed ID: 21986133
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor stimulates translocation of the class II phosphoinositide 3-kinase PI3K-C2beta to the nucleus.
Banfic H; Visnjic D; Mise N; Balakrishnan S; Deplano S; Korchev YE; Domin J
Biochem J; 2009 Jul; 422(1):53-60. PubMed ID: 19496756
[TBL] [Abstract][Full Text] [Related]
15. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
[TBL] [Abstract][Full Text] [Related]
16. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
[TBL] [Abstract][Full Text] [Related]
17. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
[TBL] [Abstract][Full Text] [Related]
18. Class II PI3Ks α and β Are Required for Rho-Dependent Uterine Smooth Muscle Contraction and Parturition in Mice.
Sarker MAK; Aki S; Yoshioka K; Kuno K; Okamoto Y; Ishimaru K; Takuwa N; Takuwa Y
Endocrinology; 2019 Jan; 160(1):235-248. PubMed ID: 30476019
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
